Reviews
12 April 2024
Vol. 16 No. 4 (2024)
CD4/CD8 double-negative mycosis fungoides: a review
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2931
Views
559
Downloads
11
HTML
Authors
Mycosis fungoides (MF) stands as the predominant form of primary cutaneous T-cell lymphoma (CTCL). It manifests a diverse array of clinical, histological, and immunophenotypic variations, each bearing distinct prognostic implications. The typical immunophenotypic profile of mycosis fungoides involves CD3+/CD4+/CD45RO+ memory T cells. Notably, the CD4- /CD8- double-negative variant of MF is a rare occurrence, observed in approximately 12% of early-stage cases and more prevalent in tumor-stage instances, often correlated with atypical clinical presentations. Despite its rarity, scant information is available about double-negative mycosis fungoides, with only a limited number of cases documented in the existing literature. This review aims to provide enhanced clarity, comprehension, and a detailed exploration of the spectrum encompassing double-negative mycosis fungoides.
Altmetrics
Downloads
Download data is not yet available.
Citations
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-85.
Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res 2016;5:F1000.
Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978-88.
Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65.
Fujii K. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Front Oncol 2018;8:198.
Amorim GM, Niemeyer-Corbellini JP, Quintella DC, et al. Clinical and epidemiological profile of patients with early stage mycosis fungoides. An Bras Dermatol 2018;93:546-552.
Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-66.
Zinzani PL, Ferreri AJ, Cerroni L. Mycosis fungoides. Crit Rev Oncol Hematol 2008;65:172-82.
Furue M, Kadono T. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome. J Dermatol 2015;42:941-4.
Martínez-Escala ME, González BR, Guitart J. Mycosis Fungoides Variants. Surg Pathol Clin 2014;7:169-89.
Hodak E, David M, Maron L, et al. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides. J Am Acad Dermatol 2006;55:276-84.
Fierro MT, Novelli M, Savoia P, et al. CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients. J Cutan Pathol 2001;28:356-62.
Massone C, Crisman G, Kerl H, Cerroni L. The prognosis of early mycosis fungoides is not influenced by phenotype and Tcell clonality. Br J Dermatol 2008;159:881-6.
Cho-Vega JH, Tschen JA, Vega F. CD4/CD8 double-negative early-stage mycosis fungoides associated with primary cutaneous follicular center lymphoma. J Am Acad Dermatol 2011;65:884-886.
Kempf W, Kazakov DV, Cipolat C, et al. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression-- a disease of follicular helper T-cells? Am J Dermatopathol 2012;34:757-61.
Nagase K, Shirai R, Okawa T, et al. CD4/CD8 double-negative mycosis fungoides mimicking erythema gyratum repens in a patient with underlying lung cancer. Acta Derm Venereol 2014;94:89-90.
Ito A, Sugita K, Ikeda A, Yamamoto O. CD4/CD8 Doublenegative Mycosis Fungoides: A Case Report and Literature Review. Yonago Acta Med 2019;62:153-158.
Shon U, Yun DK, Seong GH, et al. CD4/CD8 double-negative early-stage mycosis fungoides with CD30 expression. J Cutan Pathol 2021;48:587-589.
Haghayeghi K, Robinson-Bostom L, Olszewski A, et al. Aggressive CD4/CD8 Double-Negative Primary Cutaneous TCell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides? Am J Dermatopathol 2021;43:63-66.
Alnasser MA, AlKhawajah NM, AlQadri NG, et al. Erythrodermic CD4/CD8 Double-Negative Mycosis Fungoides: A Case Report. Case Rep Oncol 2021;14:256-261.
Kasinathan G, Sathar J. Disseminated mature T-cell phenotype CD4/CD8 double-negative mycosis fungoides with pleural involvement. Hematol Transfus Cell Ther 2021:S2531-1379:00132-2.
Ballano Ruiz A, Bakali Badesa S, Gómez Mateo MC, Yus Gotor MC. Cytotoxic CD4/CD8 Double-Negative Mycosis Fungoides. Actas Dermosifiliogr 2022;113:199-201.
Wilmas KM, Aria AB, Landis LN, et al. CD4/CD8 doublenegative mycosis fungoides with large cell transformation and involvement of the lungs and leptomeninges. Dermatol Online J 2022;28.
Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014;70:205.e1-16; quiz 221-2.
Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol 2008;59(2 Suppl 1):S16-22.
Wain EM, Orchard GE, Mayou S, et al. Mycosis fungoides with a CD56+ immunophenotype. J Am Acad Dermatol 2005;53:158-63.
Santucci M, Pimpinelli N, Massi D, et al. EORTC Cutaneous Lymphoma Task Force. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-27.
Vermeer MH, Geelen FA, Kummer JA, et al. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol 1999;154:1203-10.
Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma 2013;54:752-9.
Pimpinelli N, Olsen EA, Santucci M, et al. International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.
Molloy K, Jonak C, Woei-A-Jin FJSH, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol 2020;182:770-779.
Shimauchi T, Sugita K, Nishio D, et al. Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides. J Dermatol Sci 2008;50:217-25.
Haruyama S, Sugita K, Kawakami C, et al. Development of a prominent granulomatous eruption after interferon-gamma therapy in a patient with mycosis fungoides. Acta Derm Venereol 2010;90:190-1.
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017;77:57-74.
Hamada T, Sugaya M, Tokura Y, et al. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. J Dermatol 2017;44:135-142.
Leuchte K, Schlaak M, Stadler R, et al. Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation. Oncol Res Treat 2017;40:262-269.
Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther 2019;12:1085-1094.
Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the Phase III MAVORIC Study. Blood 2017;130:817.
How to Cite
CD4/CD8 double-negative mycosis fungoides: a review. (2024). Dermatology Reports, 16(4). https://doi.org/10.4081/dr.2024.9908
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
